TO: ALL PRINCIPAL INVESTIGATORS, NURSES AND DATA MANAGERS

FROM: PROTOCOL SECTION

DATE: MARCH 16, 2020

RE: PROTOCOL NRG-GY008 – TERMINATION

A Phase II Evaluation of Copanlisib (BAY 80-6946) (IND #130822), a Selective Inhibitor of PI3KCA, in Patients with Persistent or Recurrent Endometrial Carcinoma Harboring PIK3CA Hotspot Mutations

NCI Version: March 21, 2017

Study Chair: Alessandro D. Santin, M.D., Alessandro.santin@yale.edu

Per action of the GYN Committee, NRG-GY008 is terminated effective February 14, 2020. All data collection is complete and the trial may be closed with your IRB.